Patent Publication Number: US-11654085-B2

Title: Method of making dual chamber flexible container

Description:
PRIORITY 
     This application claims priority to and the benefit of U.S. Provisional Application No. 62/673,584, filed May 18, 2018, entitled, “Dual Chamber Flexible Container And Drug Product Using Same”, the entire contents of which are hereby incorporated by reference and relied upon. 
    
    
     BACKGROUND 
     The present disclosure relates generally to medical device packaging and more specifically to drug delivery packaging. 
     Drugs such as antibiotics that are not stable in solution at room temperature over a desired shelf life can be stored in different forms to maintain stability. In a first form, the drug is premixed for use and then frozen. Here, the drug advantageously does not have to be mixed prior to delivery, but must be stored in a frozen state. Maintaining the drug in a frozen state requires a specialized storage location, costly energy, and time to thaw the drug prior to delivery. Freezing the drug is accordingly not optimal for certain healthcare providers. 
     Another way to store drugs such as antibiotics is to separate the drug from its liquid delivery medium, i.e., a diluent. Traditionally, the separation has been done by providing the powdered drug in a septum-capped vial that can be reconstituted with diluent by a hospital pharmacist. Ordinarily, this requires the pharmacist to withdraw a syringeful of diluent from a separate IV solution container, inject the diluent into the vial to dissolve the drug, withdraw the dissolved drug from the vial via syringe and reinject the drug into the IV container to prepare a drug solution ready for administration. It will be appreciated that each step of this procedure presents an opportunity for error and/or contamination of the finished drug dose. 
     A number of solutions have been proposed for reducing the amount of steps required to prepare a drug solution from a powdered drug. The MINI-BAG Plus™ product provided by the assignee of the present disclosure is one such system. As disclosed in U.S. Pat. No. 5,304,163, the MINI-BAG Plus™ product includes a diluent bag having an integrated adapter forming an admixture system. The adapter connects to a standard twenty millimeter (“mm”) closure, single-dose, powdered-drug vial. The bag holds dextrose or saline diluent. The user connects the drug vial to the adapter and then opens a frangible valve to allow the diluent to flow into the vial and dissolve the drug, and then causes the mixture to flow back into the diluent bag. The bag is also provided with an administration port. The administration port is spiked by a hollow spike of an IV administration set to allow the reconstituted drug solution in the bag to flow through a tube of the administration set via gravity or infusion pump to the patient. In a similar system described in U.S. Pat. No. 4,614,567 (“the &#39;567 Patent”), a port on an IV solution container is adapted to mate with a specially configured vial containing the powdered drug. In the &#39;567 Patent system, the vial closure and port closure can be opened together to create a fluid connection between the vial contents and the diluent in the bag. The combined contents of bag and vial can then be administered intravenously to the patient. 
     Another system separating the drug from its liquid delivery medium is described in U.S. Pat. No. 5,944,709 (“the &#39;709 Patent”). The &#39;709 Patent teaches a multi-compartment drug container for storing and mixing together diluents and drugs. The container incorporates multiple compartments, separated by peelable seals, in which the diluents and drugs are stored. The peelable seals are ruptured by manipulation of the container to thereby mix the contents together for delivery to a patient. 
     In any of the different ways to separate the drug from its liquid delivery medium, it may become expensive and difficult to provide the drug, especially in the quantities that may be needed for certain popular types of antibiotics. Certain of the previous approaches require specialized vials or significant manipulation by the pharmacist to reconstitute the drug. There thus remains a need for improved ways to keep a powdered drug separate from its liquid delivery medium, while still permitting easy reconstitution of the drug solution for patient administration. 
     SUMMARY 
     The examples described herein disclose a dual chamber flexible container, e.g., a bag, and a drug delivery product using the same. The dual chamber bag includes a diluent chamber, a drug chamber and an administration area leading to an administration port. A first, mixing peel seal is located between the diluent chamber and the drug chamber. A second, delivery peel seal is located between the drug chamber and the administration port. The mixing peel seal may have the same strength as the delivery peel seal (i.e., require approximately the same force to open the seals). Or, the mixing peel seal may be stronger or weaker than the delivery peel seal (require more or less force to open the mixing peel seal than the delivery peel seal). 
     The dual chamber bag may be made of one or more polymer sheets having two or more layers. For example, there may be three layers including a seal layer (closest to diluent and drug), a middle layer, and a skin layer (outer layer). The layers may each include one or more polymers, such as polypropylene (“PP”), propylene-ethylene copolymer (“EPR”) and/or a styrene-olefin-styrene block copolymer elastomer (commonly referred to as styrene ethylene butylene styrene (“SEBS”) or styrene ethylene propylene styrene (“SEPS”), and which may include other elastomers. The bag may be made of a single sheet, which is folded and sealed together along all sides, folded and non-folded, or along the non-folded sides only. Or, the bag may be made from separate sheets and sealed together along all sides. Such sealing may include any one or more of ultrasonic welding, heat sealing, radio-frequency induced heat sealing, solvent bonding and the like. Typically, however, carefully controlled heat sealing is performed. 
     The seals formed along the outer sides of the dual chamber bag are strong seals relative to the weaker peel seals of the bag. Variously sized and shaped apertures may be formed in at least two of the strong seals for use in hanging the dual chamber bag for administration and/or positioning the bag during sterilization and/or filling. 
     The peel seals may be straight or have a more complex, nonlinear shape. In one embodiment, a portion of the delivery peel seal has a trapezoidal shape (three sides of the trapezoid), in which the peel seal extends along the two sides and the shorter base of the trapezoid, which is set off from the longer base of the trapezoid in a direction away from the administration port of the bag. The trapezoid moves the seal away from the administration port to allow room for the port and so that the peel seal does not come too close to the port, which could pinch the sheets of the bag at the port, placing stress on the peel seal and rupturing the weak seal. The trapezoidal path allows the peel seal to exist stress free until opened. 
     The administration port of the dual chamber bag may be provided with a medically safe rubber, e.g., a thermoplastic elastomer (“TPE”) insert, which accommodates a broad range of spike heads provided with the administration sets. The administration port may be made of a harder plastic (e.g., polypropylene (“PP”)) outer port, which is fitted with the more compressible TPE insert, which is spiked by the spike head of the administration set. The TPE insert provides flexibility to accept non-standard or differently sized spikes without leakage. 
     At least one face, and in an embodiment both faces, of the drug chamber are covered by a removably affixed opaque layer, such as an aluminum foil layer. The opaque layer protects the drug within the drug chamber from light and/or air. To aid the oxygenation protection, the opaque layer may have gas-barrier properties. In an embodiment, the opaque layer is sized to cover the seals surrounding the drug chamber, including the peel seals, and is removably sealed to the outside face of the drug container substantially along the outline of the drug container defined by the permanent and peelable seals. Each opaque layer includes at least one non-sealed tab used to initiate removal of the opaque layer, which may be located adjacent to one of the seals. In an embodiment, a seal for the opaque layer extends between the delivery peel seal and the administration port, so that the seal for the opaque layer does not in any way interrupt (i) the delivery peel seal or (ii) the powdered drug chamber bounded in part by the delivery peel seal. Alternatively, the opaque layer seal may completely cover the delivery peel seal. In a further alternative embodiment, two delivery peel seals are provided, one completely covered by the opaque layer seal, the other not covered at all by the opaque layer seal. 
     The drug and diluent filled product of the present disclosure using the dual chamber bag is formed in two stages in one embodiment. In a first stage, the diluent chamber of the bag is filled with diluent e.g., dextrose, saline solution, or sterile water for injection, in a non-aseptic manner and is thereafter moist heat sterilized. In an embodiment, the dual chamber bag is subjected to steam at 120 to 125° C. for twenty to thirty minutes. In a second stage, the drug chamber of the diluent-filled dual chamber bag is aseptically filled with a drug in powder form. In one embodiment, the powder is provided in a sterilized form. Filling of the powdered drug may be aided by a temporary peel seal that is opened to inject the drug, after which the area of the container having the temporary peel seal is strong sealed. Thus, after the drug has been delivered aseptically to the drug chamber, the dual chamber bag is completely loaded and sterile. The protective opaque layer is provided in one preferred embodiment after aseptic filling of the drug powder. Very generally, the major steps of this first embodiment may include: bag forming with temporary drug peel seal, diluent filling, sterilization and drying, aseptic transfer to cleanroom, temporary drug peel seal opening, powder drug filling, drug chamber sealing, opaque layer sealing, and overpouching. 
     In one alternative embodiment, the powdered drug filling stage is performed before the diluent filling stage. Here, the diluent may have to be aseptically filled if the drug cannot withstand moist heat sterilization. 
     In another alternative embodiment, filling of both the powdered drug and the diluent is performed in an aseptic environment. Here, filling may be aided by two temporary peel seals, which are each opened to inject the powdered drug and diluent, respectively, after which the areas of the containers having the temporary peel seals are strong sealed. Very generally, the major steps of this third embodiment may include: bag forming with temporary drug and diluent peel seals, dry bag sterilization such as irradiation, aseptic transfer to cleanroom, temporary drug peel seal opening, powder drug filling, drug chamber sealing, temporary diluent peel seal opening, diluent filling, diluent chamber sealing, opaque layer sealing, and overpouching. 
     Moreover, to reduce the amount of solid material that must be aseptically filled, it is contemplated to remove one or more components of the dry drug powder (relative to known dry formulations of the drug as ordinarily supplied in vials) and to provide it instead with the liquid diluent. Components suitable for removal from the drug powder include buffers, tonicity adjusters, or other soluble additives that withstand moist heat sterilization. The removed one or more components are provided instead in the liquid diluent. 
     In light of the embodiments discussed herein, and without limiting the present disclosure in any way, in a first aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a multiple chamber container includes: a first sheet; a second sheet; a first peel seal between the first and second sheets, the first peel seal extending across the first and second sheets; wherein at a first time at least one strong seal is provided around a periphery of the first and second sheets so as to leave an opening between the first and second sheets, and wherein a second peel seal is provided between the first and second sheets, the second peel seal extending across the opening between the first and second sheets; and wherein at a second time the second peel seal is removed and the at least one strong seal is extended to seal the opening between the first and second sheets. 
     In a second aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, the first peel seal extends between the periphery of the first and second sheets and divides the container into multiple chambers. 
     In a third aspect of the present disclosure, which may be combined with the second aspect in combination with any other aspect unless specified otherwise, one of the chambers is provided to accept a powdered drug, and wherein the second peel seal extends across the opening between the first and second sheets at a peripheral portion of the powdered drug chamber. 
     In a fourth aspect of the present disclosure, which may be combined with the second aspect in combination with any other aspect unless specified otherwise, one of the chambers is provided to accept a diluent, wherein the opening between the first and second sheets is a first opening, and wherein at the first time a second opening is provided at a portion of the periphery of the diluent chamber to allow diluent to be added to the diluent chamber. 
     In a fifth aspect of the present disclosure, which may be combined with the fourth aspect in combination with any other aspect unless specified otherwise, at the second time the at least one strong seal is extended to seal the second opening between the first and second sheets. 
     In a sixth aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, at the first time a third peel seal is provided between the first and second sheets, the third peel seal extending across the first and second sheets so as to restrict access to an outlet of the multiple chamber container. 
     In a seventh aspect of the present disclosure, which may be combined with the sixth aspect in combination with any other aspect unless specified otherwise, the outlet of the multiple chamber container includes an administration port. 
     In an eighth aspect of the present disclosure, which may be combined with the sixth aspect in combination with any other aspect unless specified otherwise, a sealing strength of the first peel seal is greater than a sealing strength of the third peel seal, and wherein the sealing strength of the third peel seal is greater than a sealing strength of the second peel seal. 
     In a ninth aspect of the present disclosure, which may be combined with the sixth aspect in combination with any other aspect unless specified otherwise, a width of the third peel seal is greater than or equal to a width of the second peel seal. 
     In a tenth aspect of the present disclosure, which may be combined with the sixth aspect in combination with any other aspect unless specified otherwise, at the second time the third peel seal remains, while the second peel seal is removed. 
     In an eleventh aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, the second peel is sized to extend into the at least one peripheral strong seal. 
     In a twelfth aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a multiple chamber container includes a first sheet; a second sheet; a first peel seal between the first and second sheets, the first peel seal extending across the first and second sheets; a second peel seal between the first and second sheets, the second peel seal extending across the first and second sheets; and a third peel seal between the first and second sheets, the third peel seal extending along a periphery of the first and second sheets. 
     In a thirteenth aspect of the present disclosure, which may be combined with the twelfth aspect in combination with any other aspect unless specified otherwise, the first peel seal is wider than the second peel seal, and wherein the second peel seal has a same width or is wider than the third peel seal. 
     In a fourteenth aspect of the present disclosure, which may be combined with the twelfth aspect in combination with any other aspect unless specified otherwise, the third peel seal is at least substantially straight, and wherein at least one of the first and second seals is non-linear. 
     In a fifteenth aspect of the present disclosure, which may be combined with the twelfth aspect in combination with any other aspect unless specified otherwise, a sealing strength of the first peel seal is greater than a sealing strength of the second peel seal, and wherein the sealing strength of the second peel seal is greater than a sealing strength of the third peel seal. 
     In a sixteenth aspect of the present disclosure, which may be combined with the twelfth aspect in combination with any other aspect unless specified otherwise, the first and second peel seals extend across the first and second sheets to at least one peripheral strong seal between the first and second sheets. 
     In a seventeenth aspect of the present disclosure, which may be combined with the twelfth aspect in combination with any other aspect unless specified otherwise, the third peel seal is formed with an opening sized to accept a gas injecting structure. 
     In an eighteenth aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a multiple chamber container formed and filled by a method includes: forming at least one strong seal around a periphery of first and second sheets so as to leave an opening between the first and second sheets; forming a temporary peel seal across the opening; forming a mixing peel seal between the first and second sheets so as to separate a diluent chamber from a powdered drug chamber; adding diluent to the diluent chamber; sterilizing the multiple chamber container including the diluent; opening the temporary peel seal in an aseptic environment; adding powdered drug to the powdered drug chamber through the opening; and strong sealing the opening so as to be closed. 
     In a nineteenth aspect of the present disclosure, which may be combined with the eighteenth aspect in combination with any other aspect unless specified otherwise, the opening is a first opening, and wherein forming the at least one strong seal around the periphery of the first and second sheets includes leaving a second opening between the first and second sheets for filling the diluent. 
     In a twentieth aspect of the present disclosure, which may be combined with the nineteenth aspect in combination with any other aspect unless specified otherwise, the method forming the multiple chamber container includes strong sealing the second opening so as to be closed prior to sterilizing the multiple chamber container. 
     In a twenty-first aspect of the present disclosure, which may be combined with the eighteenth aspect in combination with any other aspect unless specified otherwise, the method forming the multiple chamber container includes forming a delivery peel seal between the powdered drug chamber and an outlet of the multiple chamber container. 
     In a twenty-second aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a multiple chamber container includes: a first sheet; a second sheet; a first peel seal between the first and second sheets, the first peel seal extending across the first and second sheets to form first and second chambers; wherein at a first time at least one strong seal is provided around a periphery of the first and second sheets so as to leave first and second openings for the first and second chambers, respectively, between the first and second sheets, wherein a second peel seal is provided between the first and second sheets, the second peel seal extending across the first opening between the first and second sheets, and wherein a third peel seal is provided between the first and second sheets, the third peel seal extending across the second opening between the first and second sheets; and wherein at a second time the second and third peel seals are removed and the at least one strong seal is extended to seal the first and second openings between the first and second sheets. 
     In a twenty-third aspect of the present disclosure, which may be combined with the twenty-second aspect in combination with any other aspect unless specified otherwise, at the first time a fourth peel seal is provided between the first and second sheets, the fourth peel seal extending across the first and second sheets so as to restrict access to an outlet of the multiple chamber container. 
     In a twenty-fourth aspect of the present disclosure, which may be combined with the twenty-third aspect in combination with any other aspect unless specified otherwise, the outlet of the multiple chamber container includes an administration port. 
     In a twenty-fifth aspect of the present disclosure, which may be combined with the twenty-third aspect in combination with any other aspect unless specified otherwise, a sealing strength of the first peel seal is greater than a sealing strength of the fourth peel seal, and wherein the sealing strength of the fourth peel seal is greater than a sealing strength of the second and third peel seals. 
     In a twenty-sixth aspect of the present disclosure, which may be combined with the twenty-third aspect in combination with any other aspect unless specified otherwise, a width of the fourth peel seal is greater than or equal to a width of the second and third peel seals. 
     In a twenty-seventh aspect of the present disclosure, which may be combined with the twenty-third aspect in combination with any other aspect unless specified otherwise, at the second time the first and the fourth peel seals remain, while the second and third peel seals are removed. 
     In a twenty-eighth aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a multiple chamber container formed and filled by a method including: forming at least one strong seal around a periphery of first and second sheets so as to leave first and second openings between the first and second sheets; forming a first temporary peel seal across the first opening; forming a second temporary peel seal across the second opening; forming a mixing peel seal between the first and second sheets so as to separate a powdered drug chamber from a diluent chamber; opening the first temporary peel seal in an aseptic environment; adding powdered drug to the powdered drug chamber through the first opening; strong sealing the first opening so as to be closed; opening the second temporary peel seal in an aseptic environment; adding diluent to the diluent chamber through the second opening; and strong sealing the second opening so as to be closed. 
     In a twenty-ninth aspect of the present disclosure, which may be combined with the twenty-eighth aspect in combination with any other aspect unless specified otherwise, the multiple chamber container formed and filled by the method includes forming a delivery peel seal between the powdered drug chamber and an outlet of the multiple chamber container. 
     In a thirtieth aspect of the present disclosure, which may be combined with the twenty-eighth aspect in combination with any other aspect unless specified otherwise, at least one of (i) the first opening and the first temporary peel seal extend along the powdered drug chamber or (ii) the second opening and the second temporary peel seal extend along the diluent chamber. 
     In a thirty-first aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a multiple chamber container product includes: a diluent chamber; a drug chamber; an administration port; strong seals sealing an outside of the diluent chamber and drug chamber; a first peel seal located between the diluent chamber and the drug chamber; a second peel seal located between the drug chamber and the administration port; a powdered drug missing at least one component normally provided with the powdered drug; and a pharmaceutically acceptable diluent solution including the at least one component normally provided with the powdered drug. 
     In a thirty-second aspect of the present disclosure, which may be combined with the thirty-first aspect in combination with any other aspect unless specified otherwise, the at least one component normally provided with the powdered drug includes a buffer or a tonicity adjuster. 
     In a thirty-third aspect of the present disclosure, which may be combined with the thirty-first aspect in combination with any other aspect unless specified otherwise, the powdered drug is an antibiotic. 
     In a thirty-fourth aspect of the present disclosure, which may be combined with the thirty-first aspect in combination with any other aspect unless specified otherwise, the diluent includes dextrose or saline. 
     In a thirty-fifth aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a multiple chamber container includes: plural opposing layers of a flexible film, said layers permanently sealed together with a peripheral seal to define an interior fluid space; a first peelable seal formed between the film layers and defining a diluent chamber at one end of the fluid space; an administration port disposed in the peripheral seal remote from the diluent chamber and providing a flow pathway out of the fluid space; and a second peelable seal obstructing fluid flow between the interior fluid space and the administration port, wherein the first and second peelable seals and the peripheral seal define a drug chamber between the diluent chamber and the administration port, and wherein a central portion of the second peel seal is non-linear and extended away from the administration port a distance sufficient such that the non-linear central portion of the second peel seal is substantially unstressed by the administration port. 
     In another aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a delivery peel seal is provided that obstructs access to an administration port, wherein the delivery peel seal includes first and second seals, the first seal covered by an opaque layer seal to the container, the second peel seal uncovered by the opaque layer seal to the container. 
     In a thirty-sixth aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a multiple chamber container forming and filling method includes: forming at least one strong seal around a periphery of first and second sheets so as to leave an opening between the first and second sheets; forming a temporary peel seal across the opening; forming a mixing peel seal between the first and second sheets so as to separate a diluent chamber from a powdered drug chamber; adding diluent to the diluent chamber; sterilizing the multiple chamber container including the diluent; opening the temporary peel seal in an aseptic environment; adding powdered drug to the powdered drug chamber through the opening; and strong sealing the opening so as to be closed. 
     In a thirty-seventh aspect of the present disclosure, which may be combined with the thirty-sixth aspect in combination with any other aspect unless specified otherwise, the opening is a first opening, and wherein forming the at least one strong seal around the periphery of the first and second sheets includes leaving a second opening between the first and second sheets for adding the diluent. 
     In a thirty-eighth aspect of the present disclosure, which may be combined with the thirty-seventh aspect in combination with any other aspect unless specified otherwise, the method includes strong sealing the second opening so as to be closed prior to sterilizing the multiple chamber container. 
     In a thirty-ninth aspect of the present disclosure, which may be combined with the thirty-sixth aspect in combination with any other aspect unless specified otherwise, the method includes forming a delivery peel seal between the powdered drug chamber and an outlet of the multiple chamber container. 
     In a fortieth aspect of the present disclosure, which may be combined with the thirty-sixth aspect in combination with any other aspect unless specified otherwise, forming the temporary peel seal across the opening includes leaving a smaller opening in the temporary peel seal to accept a gas injecting structure. 
     In a forty-first aspect of the present disclosure, which may be combined with the fortieth aspect in combination with any other aspect unless specified otherwise, the method includes closing the smaller opening after inserting gas through the smaller opening. 
     In a forty-second aspect of the present disclosure, which may be combined with the thirty-sixth aspect in combination with any other aspect unless specified otherwise, the method includes inserting gas into the powdered drug chamber prior to opening the temporary peel seal. 
     In a forty-third aspect of the present disclosure, which may be combined with the forty-second aspect in combination with any other aspect unless specified otherwise, the gas is at least one of an inerting gas or an oxygen getting gas. 
     In a forty-fourth aspect of the present disclosure, which may be combined with the forty-second aspect in combination with any other aspect unless specified otherwise, the gas separates the first and second sheets, and wherein opening the temporary peel seal includes suctioning the separated first and second sheets and pulling on the temporary peel seal. 
     In a forty-fifth aspect of the present disclosure, which may be combined with the thirty-sixth aspect in combination with any other aspect unless specified otherwise, the opening and the temporary peel seal border the powdered drug chamber. 
     In a forty-sixth aspect of the present disclosure, which may be combined with the thirty-sixth aspect in combination with any other aspect unless specified otherwise, the method includes sterilizing the powdered drug prior to adding the powdered drug to the powdered drug chamber through the opening. 
     In a forty-seventh aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a container forming and filling method includes: forming at least one strong seal around a periphery of first and second sheets so as to leave an opening between the first and second sheets; forming a temporary peel seal across the opening; injecting gas through the temporary peel seal to separate the first and second sheets; pulling the separated first and second sheets to open the temporary peel seal in an aseptic environment; adding powdered drug to the multiple chamber container through the opening; and strong sealing the opening so as to be closed. 
     In a forty-eighth aspect of the present disclosure, which may be combined with the forty-seventh aspect in combination with any other aspect unless specified otherwise, injecting gas through the temporary peel seal includes providing a smaller opening in the temporary peel seal and injecting the gas via the smaller opening. 
     In a forty-ninth aspect of the present disclosure, which may be combined with the forty-seventh aspect in combination with any other aspect unless specified otherwise, pulling the separated first and second sheets to open the temporary peel seal includes applying suction cups to the first and second sheets and pulling the suction cups apart. 
     In a fiftieth aspect of the present disclosure, which may be combined with the forty-seventh aspect in combination with any other aspect unless specified otherwise, the method includes forming an administration port, sealing the administration port between and to the first and second sheets, and sterilizing the multiple chamber container including the administration port. 
     In a fifty-first aspect of the present disclosure, which may be combined with the forty-seventh aspect in combination with any other aspect unless specified otherwise, injecting gas through the temporary peel seal between the first and second sheets is performed prior to sterilization of the container or in an aseptic environment. 
     In a fifty-second aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a method is provided for a multiple chamber container including a diluent chamber, a drug chamber, an administration port, a first peel seal located between the diluent chamber and drug chamber, and a second peel seal located between the drug chamber and the administration port, the method including: filling the diluent chamber with diluent non-aseptically; sealing the diluent chamber completely; sterilizing the dual chamber bag including the diluent; filling the drug chamber aseptically with a presterilized drug; and sealing the drug chamber completely. 
     In a fifty-third aspect of the present disclosure, which may be combined with the fifty-second aspect in combination with any other aspect unless specified otherwise, sterilizing the dual chamber bag including the diluent includes steam sterilizing or radiation sterilizing the dual chamber bag. 
     In a fifty-fourth aspect of the present disclosure, which may be combined with the fifty-second aspect in combination with any other aspect unless specified otherwise, filling the drug chamber aseptically with a presterilized drug includes filling the drug chamber through the administration port. 
     In a fifty-fifth aspect of the present disclosure, which may be combined with the fifty-second aspect in combination with any other aspect unless specified otherwise, sealing the drug chamber completely includes sealing a seal forming the drug chamber. 
     In a fifty-sixth aspect of the present disclosure, which may be combined with the fifty-second aspect in combination with any other aspect unless specified otherwise, the method further includes applying a vacuum to the drug chamber prior to filling the drug chamber aseptically with the presterilized drug. 
     In a fifty-seventh aspect of the present disclosure, which may be combined with the fifty-second aspect in combination with any other aspect unless specified otherwise, the method further includes purging the drug chamber with an inert gas prior to filling the drug chamber aseptically with the presterilized drug. 
     In a fifty-eighth aspect of the present disclosure, which may be combined with the fifty-second aspect in combination with any other aspect unless specified otherwise, wherein filling the drug chamber aseptically with the presterilized drug and sealing the drug chamber completely occurs before filling the diluent chamber with diluent non-aseptically, sealing the diluent chamber completely, and sterilizing the dual chamber bag including the diluent. 
     In a fifty-ninth aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a multiple chamber container forming and filling method includes: forming at least one strong seal around a periphery of first and second sheets so as to leave first and second openings between the first and second sheets; forming a first temporary peel seal across the first opening; forming a second temporary peel seal across the second opening; forming a mixing peel seal between the first and second sheets so as to separate a powdered drug chamber from a diluent chamber; opening the first temporary peel seal in an aseptic environment; adding powdered drug to the powdered drug chamber through the first opening; strong sealing the first opening so as to be closed; opening the second temporary peel seal in an aseptic environment; adding diluent to the diluent chamber through the second opening; and strong sealing the second opening so as to be closed. 
     In a sixtieth aspect of the present disclosure, which may be combined with the fifty-ninth aspect in combination with any other aspect unless specified otherwise, the method includes forming a delivery peel seal between the powdered drug chamber and an outlet of the multiple chamber container. 
     In a sixty-first aspect of the present disclosure, which may be combined with the fifty-ninth aspect in combination with any other aspect unless specified otherwise, the method includes at least one of (i) extending the first opening and the first temporary peel seal along the powdered drug chamber or (ii) extending the second opening and the second temporary peel seal along the diluent chamber. 
     In a sixty-second aspect of the present disclosure, which may be combined with the fifty-ninth aspect in combination with any other aspect unless specified otherwise wherein at least one of (i) forming the first temporary peel seal across the first opening includes leaving a smaller opening in the first temporary peel seal to accept a gas injecting structure or (ii) forming the second temporary peel seal across the second opening includes leaving a smaller opening in the second temporary peel seal to accept a gas injecting structure. 
     In a sixty-third aspect of the present disclosure, which may be combined with the fifty-ninth aspect in combination with any other aspect unless specified otherwise, the method includes closing at least one of the smaller openings after inserting gas through the at least one smaller opening. 
     In a sixty-fourth aspect of the present disclosure, which may be combined with the fifty-ninth aspect in combination with any other aspect unless specified otherwise, the method includes inserting gas into at least one of the powdered drug chamber or the diluent chamber prior to opening the temporary peel seal. 
     In a sixty-fifth aspect of the present disclosure, which may be combined with the sixty-fourth aspect in combination with any other aspect unless specified otherwise, the gas is at least one of an inerting gas or an oxygen getting gas. 
     In a sixty-sixth aspect of the present disclosure, which may be combined with the sixty-fourth aspect in combination with any other aspect unless specified otherwise, the gas separates the first and second sheets, and wherein opening at least one of the first or second temporary peel seals includes suctioning the separated first and second sheets and pulling on the at least one of the temporary peel seals. 
     In a sixty-seventh aspect of the present disclosure, which may be combined with any other aspect unless specified otherwise, a container forming and filling method includes: forming at least one strong seal around a periphery of first and second sheets so as to leave first and second openings between the first and second sheets; forming first and second temporary peel seals across the first and second openings, respectively; injecting gas through the first and second temporary peels seal to separate the first and second sheets; pulling the separated first and second sheets to open the first and second temporary peel seals in an aseptic environment; adding powdered drug through the first opened temporary peel seal; adding diluent through the second opened temporary peel seal; and strong sealing the opened first and second temporary peel seals so as to be closed. 
     In a sixty-eighth aspect of the present disclosure, which may be combined with the sixty-seventh aspect in combination with any other aspect unless specified otherwise, injecting gas through the first and second temporary peel seals includes providing a smaller opening in each of the first and second temporary peel seals and injecting the gas via the smaller openings. 
     In a sixty-ninth aspect of the present disclosure, which may be combined with the sixty-seventh aspect in combination with any other aspect unless specified otherwise, pulling the separated first and second sheets to open the first and second temporary peel seals includes (i) applying first suction cups to the first and second sheets adjacent the first temporary peel seal and pulling the first suction cups apart and (ii) applying second suction cups to the first and second sheets adjacent the second temporary peel seal and pulling the second suction cups apart. 
     In a seventieth aspect of the present disclosure, which may be combined with the sixty-seventh aspect in combination with any other aspect unless specified otherwise, the method includes forming an administration port, sealing the administration port between and to the first and second sheets, and sterilizing the multiple chamber container including the administration port. 
     In a seventy-first aspect of the present disclosure, which may be combined with the sixty-seventh aspect in combination with any other aspect unless specified otherwise, injecting gas through the first and second temporary peel seals is performed prior to sterilization of the container or in an aseptic environment. 
     Moreover, any of the structure, functionality and alternatives disclosed in connection with  FIGS.  1 A to  13    and the claims below may be combined with any of the other structure, functionality and alternatives disclosed in connection with  FIGS.  1 A to  13    and the claims. For example, different aspects of the flexible container, flexible container product and flexible container methods recited in the claims below may be combined with each other, and wherein the resulting combinations are expressly contemplated as being within the scope of the present disclosure. 
     In light of the present disclosure including the above aspects, it is therefore an advantage of the present disclosure to provide an improved dual chamber bag. 
     It is another advantage of the present disclosure to provide an improved dual chamber bag, which virtually guarantees that patients will receive a properly mixed drug. 
     It is a further advantage of the present disclosure to provide improved ways of loading and sterilizing the contents of dual chamber bags. 
     It is yet another advantage of the present disclosure to provide an improved way to distribute the components of drugs and diluent used to fill different compartments of a dual chamber bag. 
     The advantages discussed herein may be found in one, or some, and perhaps not all of the embodiments disclosed herein. It should also be appreciated that any numeric values, such as distances and force values, provided herein are for purposes of enablement by example only, and are in no way meant to be a required feature unless specifically recited in any of the claims. Additional features and advantages are described herein, and will be apparent from, the following Detailed Description and the figures. 
    
    
     
       BRIEF DESCRIPTION OF THE FIGURES 
         FIG.  1 A  is a top-front perspective view of one embodiment of a dual chamber container or bag of the present disclosure. 
         FIG.  1 B  is a top-front perspective view of the dual chamber bag of  FIG.  1 A  showing opaque cover layers exploded or removed from the sheets of the container or bag. 
         FIG.  2    is a front view of the dual chamber container or bag of  FIGS.  1 A and  1 B . 
         FIG.  3    is a rear view of the dual chamber container or bag of  FIGS.  1 A and  1 B . 
         FIG.  4    is a side view of the dual chamber container or bag of  FIGS.  1 A and  1 B . 
         FIG.  5    is a top plan view of the dual chamber container or bag of  FIGS.  1 A and  1 B . 
         FIG.  6    is a bottom plan view of the dual chamber container or bag of  FIGS.  1 A and  1 B . 
         FIGS.  7 A to  7 C  are partially sectioned side views of the dual chamber container or bag illustrating one embodiment for a relative location between a delivery peel seal and opaque cover peel seals. 
         FIGS.  8 A to  8 C  are partially sectioned side views of the dual chamber container or bag illustrating another embodiment for a relative location between multiple delivery peel seals and opaque cover peel seals. 
         FIG.  9    is an elevation partial sectioned view of one embodiment of the administration port of the dual chamber container or bag of the present disclosure. 
         FIGS.  10 A to  10 D  are front views illustrating different manufacturing stages of one embodiment for making a dual chamber container or bag of the present disclosure. 
         FIG.  11    is a schematic diagram further illustrating the method of  FIGS.  10 A to  10 D  for making the dual chamber container or bag of the present disclosure. 
         FIGS.  12 A to  12 E  are front views illustrating different manufacturing stages of an alternative embodiment for making a dual chamber container or bag of the present disclosure. 
         FIG.  13    is a schematic diagram illustrating in cooperation with  FIGS.  12 A to  12 E  an alternative embodiment for making the dual chamber container or bag of the present disclosure. 
     
    
    
     DETAILED DESCRIPTION 
     Dual Chamber Container or Bag 
     Referring now to the drawings,  FIGS.  1 A to  9    illustrate various embodiments of a dual chamber container or bag  10 . Dual chamber bag  10  includes a first sheet  12  sealed to a second sheet  14 . Sheets  12  and  14  may each be made of a single layer or may instead include two or more layers laminated together or coextruded. For example, sheets  12  and  14  may each have three layers including a seal layer (closest to diluent and drug), a middle layer, and a skin layer (outer layer). The seal layer may include a compound of homo polypropylene (“homo PP”) and a propylene-ethylene copolymer (“EPR”), wherein amorphous domain EPR is finely dispersed in a homo PP matrix. The middle layer may include a compound of homo PP with a styrene elastomer (e.g., styrene ethylene butylene styrene (“SEBS”) or styrene ethylene propylene styrene (“SEPS”)). The skin layer may include a compound of homo PP and EPR, wherein the EPR is finely dispersed in a homo PP matrix, and wherein the content of EPR may be less than that of the seal layer. 
     For purposes of illustration only, dual chamber bag  10  will be described in terms of how it is to be arranged for use with its administration port  16  located at the bottom of the bag and extending downwardly to aid gravity flow. Upper seam  30  is formed having a strong seal. A strong seal as used herein is a seal that will not rupture under the force applied by a user to open any of the peel seals discussed herein. In an embodiment, any strong seal discussed herein may have a seal strength of at least about 30 N/15 mm. A user will be instructed to press or roll bag  10  at a location containing the diluent to build fluid pressure to rupture the peel seals. A strong seal as used herein will not rupture under such fluid pressure. The seals of any of the seams discussed herein are typically sealed via heat sealing. Seal strength may be varied by controlling the seal temperature, for example. 
     In a non-limiting example, upper seam  30  is a relatively wide seam, which may have a widest width from about 12 millimeters (“mm”) to about 25 mm, and which in one example instance is 18 mm. The length of upper seam  30  may be from about 150 mm to about 180 mm, and in one embodiment is 165 mm (the width of seam  30  may therefore be 10% to 11% of the length of the seam in one embodiment). The width of upper seam  30  as illustrated provides room and strength against tearing for one or more aperture  32 ,  34  and  36  formed in upper seam  30 , which may be circular or oblong as illustrated. Aperture  34  may be used to hang bag  10  from an intravenous (“IV”) stand or pole, while apertures  32  and  36  may be used to position bag  10  for either one or both of sterilization and/or filling. In the illustrated embodiment, seam  30  is narrowed and rounded at corners  38   a  and  38   b  of diluent chamber  70 , to (i) increase the internal volume of and (ii) avoid sharp corners for chamber  70 . 
     In an embodiment, upper seam at area  34   a  around oval  34  is reinforced either with additional material and/or additional sealing energy and/or additional sealing time. Reinforced area  34   a  helps to hold the entire weight of completely full bag  10  without tearing. Area  34   a  around oval  34  may include an additional piece of polymer material, which is welded to the rest of upper seam  30  to seal an aperture that allows diluent chamber  70  to be filled with liquid diluent. 
     Side seams  40   a  and  40   b  in an embodiment are generally mirror images of each other and are numbered the same accordingly. Side seams  40   a  and  40   b  extend from upper seam  30  and, like seam  30 , are formed having strong seals. Side seams  40   a  and  40   b  each include a narrow portion  42 , which extends along the majority of the corresponding side of diluent chamber  70 . In a non-limiting example, narrow portion  42  may have a width of about 4 mm to about 10 mm, and in one example instance is 6 mm. The length of narrow portion  42  will vary depending upon the size of bag  10 , which may in non-limiting examples be provided in three different sizes, such as, a 100 milliliter (“mL”) diluent bag  10 , a 100 mL diluent bag, a 200 mL diluent bag, and a 400 mL diluent bag. Different or additional sizes may also be provided, e.g., less than 100 mL and/or greater than 400 mL. 
     Narrow portions  42  of side seams  40   a  and  40   b  extend to curved or angled corners  44 , which increase the strong sealed area in a rounded, elliptical, parabolic or triangular way. Curved or angled corners  44  provide room and strength for one or more aperture  46 , e.g., circular aperture, if desired, which may also be used to position bag  10  for either one or both of sterilization and/or filling. Curved or angled corners  44  also funnel diluent within diluent chamber  70  towards a mixing peel seal  60  discussed in detail below. Funneling diluent towards mixing peel seal  60  helps to maximize the seal opening pressure per force applied by the user. 
     Powdered drug portions  48   a  and  48   b  of side seams  40   a  and  40   b , respectively, extend from curved or angled corners  44  of the side seams to a bottom seam  50 . In a non-limiting example, powdered drug portions  48   a  and  48   b  of the side seams may be from about 5 mm to about 12 mm wide, and in one example instance may be 10 mm wide. In a non-limiting example, the lengths of powdered drug portions  48   a  and  48   b  of the side seams extending from curved or angled corners  44  to bottom seam  50  may each be about 100 mm to about 120 mm. As discussed, narrow portions  42 , curved or angled corners  44 , and powdered drug portions  48   a  and  48   b  of side seams  40   a  and  40   b , respectively, are each formed having strong seals. 
     Bottom seam  50  is likewise a strong seam and in a non-limiting example may be from about 145 mm long to about 170 mm long, and in one example instance may be 155 mm long. Bottom seam  50  may therefore be longer or shorter than upper seam  30 . The width of bottom seam  50  varies due to the shape of powdered drug chamber  80  and the shape of an administration area  98  located between drug chamber  80  and administration port  16 . In an embodiment, the width of bottom seam  50  is greatest at the corners of bottom seam  50 , which may include or define apertures  52  that may be used to position bag  10  for sterilization and/or filling, while the width of bottom seam  50  is smallest at its center section  54 , which is sealed to administration port  16 . 
     Administration port  16  in the illustrated embodiment includes a hollow port body  18 , which may be a molded, e.g., injection molded, rigid PP structure. Administration port  16  includes a port body  18  having a tapered sealing portion  20  that extends to a cylindrical outlet portion  22 , which resides outside of bag  10 . Tapered sealing portion  20  is sealed between sheets  12  and  14  at center section  54  of seam  50 , e.g., via ultrasonic welding, heat sealing, solvent bonding, and the like. The tapered shape of sealing portion  20  prevents sheets  12  and  14  at center section  54  from having to form a sharp radius to seal around a circular port section, which could lead to a faulty seal. Outlet portion  22  of port body  18  includes a flange  22   a  at its end for receiving a spike from a mating administration set and to provide an increased area for sealing to a tear strip  28 . 
     In the illustrated embodiment, a compliant or compressible insert or sleeve  24  is fitted sealingly inside outlet portion  22  and flange  22   a  of administration port  16 , and may be formed within the port via successive molding steps. Insert or sleeve  24  may be formed from a medically safe rubber, e.g., a thermoplastic elastomer (“TPE”), which accommodates a broad range of spike head diameters provided with the administration sets. Rubber insert  24  provides flexibility, e.g., compressibility, to accept standard sized diameter spikes and non-standard or differently sized spikes. Outlet portion  22  of administration port  16  may be formed, e.g., injection molded, with a membrane  26 , which is pierced by the spike of the administration set to enable the reconstituted drug within bag  10  to flow to the patient. In an alternative embodiment, membrane  26  may be formed instead with insert  24 . A thin plastic tear strip  28  includes a middle section that is peel sealed to flange  22   a  of outlet portion  22 , maintaining sterility and preventing contaminants from entering and contacting rubber insert  24 , wherein such contaminants could be carried into the interior of bag  10  upon spiking. Either exposed end of tear strip  28  may be grasped by the user to tear strip  28  from flange  22   a  for spiking membrane  26  of administration port  16 . 
       FIG.  1 B  perhaps best illustrates that a mixing peel seal  60  is located between diluent chamber  70  and powdered drug chamber  80 . In one embodiment, the width of mixing peel seal  60  is from about 10 mm to about 20 mm, and is in one embodiment 15 mm. The length of peel seal  60  may extend from (i) curved or angled corner  44  to curved or angled corner  44  of side seams  40   a  and  40   b  or (ii) powdered drug portion  48   a  to powdered drug portion  48   b  of side seams  40   a  and  40   b , respectively. The force needed to open peel seal  60  in one embodiment is roughly one-quarter to one-third of the force needed to separate any of upper seam  30  or narrow portions  42  of side seams  40   a  and  40   b , forming the remainder of diluent chamber  70 . In an embodiment, the strength of mixing peel seal  60  may be about 2 to 12 N/15 mm. Mixing peel seal  60  is sufficiently strong and liquid-tight to prevent diluent in diluent chamber  70  from flowing into powdered drug chamber  80 . 
     Diluent chamber  70  as mentioned above may be sized differently in non-limiting examples to hold different maximum amounts of diluent, e.g., 100 mL, 200 mL or 400 mL. In a non-limiting example, diluent chamber  70  may have a side-to-side width from about 140 mm to about 160 mm, and in one example instance a width of 153 mm. In a non-limiting example, diluent chamber  70  may have a top (starting from area  34   a  around oval  34 ) to bottom height ranging from about 70 mm to about 170 mm. Diluent chamber  70  as illustrated in  FIGS.  1 A to  4    includes a pouch  72  formed from sheets  12  and  14 , which may be preformed or which may be formed when diluent is added. In one embodiment, even when pouch  72  is filled with diluent, sheets  12  and  14  are at least substantially upstretched. In an embodiment, pouch  72  is not filled completely with diluent. Thus, a diluent chamber  70  capable of holding 100 mL, for example, may be filled with only 50 or 75 mL, and likewise for the 200 mL and 400 mL larger diluent chambers  70 , to provide a desired amount of diluent for dissolving and delivering the drug in drug chamber  80 . 
     Powdered drug chamber  80  is located on the other side of mixing peel seal  60  from diluent chamber  70 . Powdered drug chamber  80  is sized to hold enough powdered drug to provide any feasible drug dose to the patient based upon the volume of diluent provided in diluent chamber  70 . In a non-limiting example, powdered drug chamber  80  may have a side to side (inner edges of side  84   a  to inner edge of side  84   b ) width from about 130 mm to about 150 mm, and in one example instance have a width of 140 mm. In one non-limiting example, powdered drug chamber  80  may have a top (at mixing peel seal  60 ) to bottom (at delivery peel seal  90 ) height ranging from about 70 mm to about 170 mm. 
     In the illustrated embodiment, powdered drug chamber  80  includes an upper edge  82  formed by mixing peel seal  60 , and two sides  84   a  and  84   b  formed by powdered drug portions  48   a  and  48   b , respectively, of side seams  40   a  and  40   b , which extend perpendicular to upper edge  82 . Powdered drug chamber  80  in the illustrated embodiment also includes two angled sides  86   a  and  86   b  formed by bottom seam  50 , which extend to center section  54  sealed to administration port  16  of bottom seam  50 . The two angled sides  86   a  and  86   b  are interrupted by delivery peel seal  90  to form the lower edge of powdered drug chamber  80 . Powdered chamber  80  may be evacuated or purged with inert gas before filling to prevent air from contacting the drug. In  FIG.  1 B , with dual chamber bag  10  hanging in the operable position such that administration port  16  points downwardly, a powdered drug  88  due to gravity falls due to gravity so as to rest on the top of delivery peel seal  90 . 
     Drug  88  may be any powdered drug capable of dissolving with a diluent, including but not limited to (i) powdered drug preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases, (ii) vaccines, (iii) anxiolytics, (iv) anti-allergics, and (v) anti-infectives. 
     In a non-limiting example, delivery peel seal  90  may be about 3 mm to about 10 mm wide and about 50 mm to about 90 mm long and have the same seal strength (force required to open), greater seal strength or a lower seal strength than mixing peel seal  60 . In an embodiment, peel seal  90  may have a seal strength of approximately 2 to 10 N/15 mm, which is the same or lower than the seal strength of mixing peel seal  60 . Delivery peel seal  90  in the illustrated embodiment has a non-linear shape, such as a trapezoidal shape. In any case, delivery peel seal  90  includes a central portion  92  that extends around an administration area  98  located between sheets  12  and  14  and directly adjacent to tapered sealing portion  20  of administration port  16 , which is sealed to center section  54  of bottom seam  50 . Placing central portion  92  instead closer to tapered sealing portion  20  runs the risk of inducing stress on peel seal  90  at portion  92  due to the sealing of sheets  12  and  14  to administration port  16 , which may cause peel seal  90  to open inadvertently. Trapezoidally or otherwise extended central portion  92  of delivery peel seal  90  ensures that the peel seal  90  is not activated under stress until the user applies pressure via mixed drug and diluent. 
     One aspect of the present disclosure is how chambers  70  and  80  interact during use via peel seals  60 ,  90 / 92  to help ensure that the opening mechanics of the dual chamber bag  10  are easy and fool proof. For example, (i) diluent and powdered drug  88  always mix before use, (ii) container  10  does not require a large manual effort to activate, and (iii) the sealing is nonetheless strong enough to withstand normal transportation and handling. Non-linear or trapezoidal portion  92 , in addition to avoiding administration port  16 , creates a stress concentration which in combination with the relative seal strengths of peel seals  60  and  90  help to meet the above-listed operational goals. Again, portion  92  may have any desired non-lineal shape. 
     As discussed, one primary purpose for the shape of non-linear portion  92  of peel seal  90  is to space peel seal  90  at portion  92  away from tapered sealing portion  20 , so that the tapered extended portion  92  is not placed under undue stress, which might cause the seal to begin to open. In the illustrated embodiment, an opaque removable cover layer  100  may be applied to one or both of sheets  12  and  14  to cover powdered drug chamber  80  and administration area  98  beneath central portion  92  of delivery peel seal  90 . Opaque layers  100  may have the same side-to-side length as the length of bottom seam  50  and extend in height from a top (or above) mixing peel seal  60  downwardly past delivery peel seal  90 . A bottom seal  102  of opaque layer  100 , in the illustrated embodiment, has the same non-linear or trapezoidal shape as peel seal  90 , including a jutting or trapezoidal portion  104  that matches portion  92  of peel seal  90 . In this manner, the existence of tapered sealing portion  20  of administration port  16  does not adversely affect bottom seal  102  of opaque layer  100 , e.g., by placing stress on the seal. 
     In one embodiment illustrated in  FIGS.  1 A,  2  and  3   , bottom seal  102  is located between delivery peel seal  90  and tapered sealing portion  20  of administration port  16 . Trapezoidal portion  104  of bottom seal  102  may overlay a portion of administration area  98 . Placing trapezoidal portion  104  of bottom seal  102  in such a location prevents bottom seal  102  from interfering (e.g., due to the formation of seal  102 ) with delivery peel seal  90  or powdered drug chamber  80 . It should be appreciated that the location of trapezoidal portion  104  may cause peel seal  90  at portion  92  to be spaced further way from tapered sealing portion  20  of administration port  16 . In an alternative embodiment discussed below, bottom seal  102  of opaque layers  100  may overlie delivery peel seal  90 . 
     Opaque layers  100  illustrated in  FIG.  1 B  may be of the same size and material, e.g., a polymer-coated aluminum foil, although the front and back layers  100  may have different markings and/or indicia. In the illustrated embodiment, bottom seal  102  of opaque layers  100  extends to angled seals  106   a  and  106   b  that extend along the widening portions of strong bottom seam  50 . Side seals  108   a  and  108   b  extend from angled seals  106   a  and  106   b  along powdered drug portions  48   a  and  48   b  of side seams  40   a  and  40   b , respectively, and in one embodiment such that opaque layers  100  completely cover drug portions  48   a  and  48   b  of the side seams. A top seal  110  of opaque layers  100  extends along mixing peel seal  60  and in one embodiment such that opaque layers  100  completely cover the mixing peel seal. All seals of opaque layers  100  are peel seals in one embodiment so that opaque layers  100  may be removed completely from container or bag  10  prior to reconstitution. 
     Opaque layers  100  extend past angled seals  106   a  and  106   b  to form tabs  112   a  and  112   b  that hinge up respectively from angled seals  106   a  and  106   b . The user may grasp either of tabs  112   a  and  112   b  to remove opaque layers  100  from sheets  12  and  14 . Seals  102 ,  106   a ,  106   b ,  108   a ,  108   b  and  110  may be formed by heat sealing at a lower temperature than that used to form peel seals  60  and  90 . Opaque layers  100  protect the powdered drug in powdered drug chamber  80  from harmful ultraviolet (“UV”) radiation and help to prevent air from entering chamber  80  through sheets  12  and  14 . 
       FIGS.  1 A,  2  and  3    illustrate one embodiment for the relative placement between bottom seal  102  of opaque layers  100  and delivery peel seal  90  formed between sheets  12  and  14  of dual chamber bag  10 .  FIGS.  7 A to  7 C  are side views of dual chamber bag  10  illustrating another embodiment for a relative placement between bottom seal  102  of opaque layers  100  and delivery peel seal  90  formed between sheets  12  and  14 . In particular, a relative placement between jutting or trapezoidal portion  104  of bottom seal  102  of opaque layers  100  and non-linear or trapezoidal portion  92  of delivery peel seal  90  is illustrated. For reference,  FIGS.  7 A to  7 C  show many of the components of dual chamber bag  10  discussed above including sheets  12  and  14  sealed to administration port  16 , wherein administration port  16  includes port body  18  having a tapered sealing portion  20  that extends to a cylindrical outlet portion  22 . Tapered sealing portion  20  is sealed between and to sheets  12  and  14 . Outlet portion  22  of port body  18  includes a flange  22   a  at its end for receiving a spike from a mating administration set and to provide an increased area for sealing to tear strip  28 . 
       FIGS.  7 A to  7 C  show opaque layers  100  separated from sheets  12  and  14  to help distinguish between same. In reality, opaque layers  100  directly abut sheets  12  and  14 . The dimensions provided in  FIGS.  7 A to  7 C  are merely an example but do aptly illustrate one possible relationship between the different peel seals, wherein delivery peel seal  90  at extended portion  92  is 5 mm wide and bottom seal  102  at trapezoidal portion  104  is 9 mm wide. Delivery peel seal  90  and bottom seal  102  of opaque layers  100  may however be of any of the widths discussed above. 
     The goal in  FIGS.  7 A to  7 C  is for bottom seal  102  of opaque layers  100  to completely cover delivery peel seal  90 . In  FIG.  7 A , the alignment between bottom seal  102  of opaque layers  100  and delivery peel seal  90  is perfect, wherein the same overshoot of 2 mm between bottom seal  102  and delivery peel seal  90  exists on both sides of delivery peel seal  90 . The seal strengths (force required to open) of seals  102  and  90  will add to increase the overall force needed to open both seals. It is contemplated, however, to instruct the user to remove opaque layers  100  prior to activating either peel seal  60  or  90  of dual chamber bag. The user will then only have to provide the force needed to open delivery peel seal  90 , e.g., 6 to 10 N/15 mm, to deliver the mixed drug. 
     In  FIG.  7 B , the misalignment of bottom seal  102  of opaque layers  100  to delivery peel seal  90  to the left is the most possible given the manufacturing process employed, wherein an overshoot of 4 mm between bottom seal  102  and delivery peel seal  90  exists to the left of delivery peel seal  90 , while no overshoot exists to the right of delivery peel seal  90 . Nevertheless, bottom seal  102  still completely covers delivery peel seal  90 . Similarly in  FIG.  7 C , the misalignment of bottom seal  102  of opaque layers  100  to delivery peel seal  90  to the right is the most possible given the manufacturing process employed, wherein an overshoot of 4 mm between bottom seal  102  and delivery peel seal  90  exists to the right of the delivery peel seal  90 , while no overshoot exists to the left of delivery peel seal  90 . Here again, bottom seal  102  still completely covers delivery peel seal  90 . It is accordingly contemplated in  FIGS.  7 A to  7 C  to size the width of bottom seal  102  and delivery peel seal  90  so that bottom seal  102  always covers delivery peel seal  90  regardless of manufacturing tolerance. 
       FIGS.  8 A to  8 C  are side views of dual chamber bag  10  illustrating a further embodiment for a relative placement between bottom seal  102  of opaque layers  100  and, here, two delivery peel seals  90  formed between sheets  12  and  14 . In particular, a relative placement between jutting or trapezoidal portion  104  of bottom seal  102  of opaque layers  100  and non-linear or trapezoidal portions  92  of two delivery peel seals  90  is illustrated. For reference,  FIGS.  8 A to  8 C  again show many of the components of dual chamber bag  10  discussed above including sheets  12  and  14  sealed to administration port  16 , wherein administration port  16  includes port body  18  having a tapered sealing portion  20  that extends to a cylindrical outlet portion  22 . Outlet portion  22  of port body  18  again includes a flange  22   a  at its end. 
       FIGS.  8 A to  8 C  show opaque layers  100  separated from sheets  12  and  14  to help distinguish between same. Again, opaque layers  100  directly abut sheets  12  and  14  in the commercial embodiment of dual chamber bag  10 . The dimensions provided in  FIGS.  8 A to  8 C  are merely an example but do aptly illustrate one possible relationship between the different peel seals, wherein both delivery peel seals  90  at extended portions  92  are 3 mm wide, while bottom seal  102  at trapezoidal portion  104  is 7 mm wide. Delivery peel seal  90  and bottom seal  102  of opaque layers  100  may, however, be of any of the widths discussed above. 
     In  FIGS.  8 A to  8 C , first and second peel seals  90 , each having a non-linear or trapezoidal portion  92 , are spaced apart from each other by a non-sealed section  94  between sheets  12  and  14 . In the illustrated embodiments, the combined width of both peel seals  90 , 6 mm, in  FIGS.  8 A to  8 C , is approximately the same as the width of peel seal  90 , 5 mm, in  FIGS.  7 A to  7 C . Thus, assuming the same amount of energy is imparted to form peel seals  90  in  FIGS.  8 A to  8 C  as the amount of energy imparted to form peel seal  90  in  FIGS.  7 A to  7 C , the seal strength of the combined peel seals  90  in  FIGS.  8 A to  8 C  should be roughly equal to the seal strength of peel seal  90  in  FIGS.  7 A to  7 C , namely, about 2 to 10 N/15 mm. 
     The goal in  FIGS.  8 A to  8 C  is for bottom seal  102  of opaque layers  100  to completely cover left delivery peel seal  90  but not at all cover right delivery peel seal  90 . In  FIG.  8 A , the alignment between bottom seal  102  of opaque layers  100  and delivery peel seals  90  is perfect, wherein the same overshoot of 2 mm between bottom seal  102  and left delivery peel seal  90  exists on both sides of left delivery peel seal  90 . Right peel seal  90  is not at all covered. As with  FIGS.  7 A to  7 C , it is contemplated to instruct the user to remove opaque layers  100  prior to activating either peel seal  60  or  90  of dual chamber bag, so that only the force needed to open both delivery peel seals  90 , e.g., 2 to 10 N/15 mm, is needed to deliver the mixed drug. 
     In  FIG.  8 B , the misalignment in the left direction between bottom seal  102  of opaque layers  100  and left delivery peel seal  90  is the most possible given the manufacturing process employed, wherein an overshoot of 4 mm in the left direction between bottom seal  102  and left delivery peel seal  90  exists, while no overshoot exists to the right of delivery peel seal  90 . Nevertheless, bottom seal  102  still completely covers left delivery peel seal  90 , while right delivery peel seal  90  remains completely uncovered by bottom seal  102 . 
     Similarly in  FIG.  8 C , the misalignment in the right direction between bottom seal  102  of opaque layers  100  and left delivery peel seal  90  is the most possible given the manufacturing process employed, wherein an overshoot of 4 mm in the right direction between bottom seal  102  and left delivery peel seal  90  exists, while no overshoot exists to the left of left delivery peel seal  90 . Nevertheless, bottom seal  102  still completely covers left delivery peel seal  90 , while right delivery peel seal  90  remains completely uncovered by bottom seal  102 . It is accordingly contemplated in  FIGS.  8 A to  8 C  to size the width of bottom seal  102  and left and right delivery peel seals  90  so that bottom seal  102  always covers left delivery peel seal  90 , while right delivery peel seal  90  is always uncovered, regardless of manufacturing tolerance. 
       FIG.  9    illustrates one preferred embodiment for administration port  16 , which is different in certain ways than administration port  16  discussed above. As before, administration port  16  includes port body  18  having a tapered sealing portion  20  forming flanges  20   a  and  20   b  (shown sectioned in  FIG.  9   ), wherein tapered sealing portion  20  extends to a cylindrical outlet portion  22 . Outlet portion  22  of port body  18  again includes a flange  22   a  for receiving tear strip  28  (illustrated above). Port body  18  is in one embodiment a molded, e.g., injection molded, rigid PP structure. 
     A compliant or compressible septum, insert or sleeve  24  is fitted sealingly inside outlet portion  22  and flange  22   a  of administration port  16 . Septum  24  may be formed from a medically safe elastomer or rubber, e.g., a thermoplastic elastomer (“TPE”), which accommodates a broad range of spike head diameters provided with the administration sets. Septum  24  may be held in place within rigid outlet portion  22  via bonding, wherein the adhesion occurs in one embodiment via a two shot injection molding process such that the materials of both septum  24  and rigid portion  22  are injected into a same injection mold to increase the bonding between both materials. The resulting bi-injection molding bond is a cohesive bond. If rigid portion  22  and septum  24  are not molded together and are instead separate parts, an adhesive may be used to bond the separate parts together. Adhesion may also be obtained during the moist heat sterilization process. Septum  24  may be unslit and allow the spike of an administration set (not illustrated) to pierce the elastomeric septum  24 , which holds the spike due to the resiliency of the material of septum  24 . In an alternative embodiment, septum  24  is preslit. 
     Elastomeric septum  24  provides flexibility, e.g., compressibility, to accept standard sized diameter spikes and non-standard or differently sized spikes. One difference between administration set  16  of  FIG.  9    and of the one described above is that a separate membrane  26  is not provided. Here, dual chamber bag  10  relies on the delivery peel seal  90  seal to separate septum  24  and port body  18  from powdered drug  88  prior to use. 
     In one embodiment, administration port  16  is fully assembled (including tear strip  28 ) prior to being sealed to sheets  12  and  14  of dual chamber container or bag  10 , which in one embodiment is performed prior to the filling of diluent or powdered drug  88 . In this way, sealed sheets  12  and  14  and sealed administration port  16  may be sterilized, e.g., steam sterilized, together. Here, tear strip  28  is configured to allow penetration of steam into port body  18 , between strip  28  and septum  24  to sterilize all contacted surfaces. 
     Method of Making 
     Referring now to  FIGS.  10 A to  10 D , dual chamber bag  10  is illustrated in various stages of manufacture. For purposes of illustration, opaque layers  100  are not shown. Also, only the element numbers relevant for  FIGS.  10 A to  10 D  are provided, however, each of the structure, functionality and alternatives discussed for any of the element numbers found in  FIGS.  1 A to  9    is applicable to dual chamber bag  10  of  FIG.  10 D  (but missing opaque layers  100 ). FIGS.  10 A to  10 D illustrate certain differences with the bag version of  FIGS.  1 A to  6   . One difference is that corners  44  in  FIGS.  10 A to  10 D  are angled instead of curved. Another difference is that an extra aperture  46  is formed in the version of  FIGS.  10 A to  10 D . 
       FIGS.  10 A,  10 B and  10 C  illustrate that in formative stages of dual chamber bag  10 , there are portions of certain peripheral edges of the bag where sheets  12  and  14  are not sealed together to have a strong seal. Those edges are indicated in dashed line. In particular,  FIGS.  10 A,  10 B and  10 C  illustrate via dashed line  128  that sheets  12  and  14  are unsealed at powdered drug strong seal portions  48   b , which is illustrated as being sealed in  FIG.  10 D . Additionally,  FIG.  10 A  illustrates via dashed line  130  that sheets  12  and  14  are unsealed at upper seam area  34   a , which is illustrated as being sealed in  FIGS.  10 B to  10 D . 
       FIGS.  10 A and  10 B  also illustrate that during the formative stages of dual chamber bag  10 , an additional lateral and temporary peel seal  120  is provided. Lateral peel seal  120  includes a first end  122  that extends to strong bottom seam  50  and a second end  124  that extends to side  40   b . Temporary peel seal  120  has a length sufficient to provide a suitable opening to receive powdered drug  88  in a later manufacturing step. In a non-limiting example, lateral peel seal  120  may be about 2 mm to about 10 mm wide and about 50 mm to about 90 mm long and have the same seal strength (force required to open), greater seal strength or a lower seal strength than delivery peel seal  90 . In an embodiment, lateral peel seal  120  may have a seal strength of approximately seal of 1 to 5 N/15 mm, and in one embodiment be 3 N/15 mm. 
     Lateral peel seal  120  in the illustrated embodiment is initially formed with a small opening or aperture  126 , which is sized to accept a discharge tube or nozzle of an injection gas filling station (not illustrated). Opening or aperture  126  may, for example, be long enough to accept a 6 mm to 10 mm outer diameter inert gas filling tube or nozzle. The injection gas may be an inert gas such as nitrogen, argon, carbon dioxide or mixtures thereof. If it becomes imperative to remove as much oxygen as possible from drug chamber  80 , an oxygen “getter” gas, such as hydrogen or silane may be used instead or in combination with any one or more of the inert gases mentioned above. 
     In the formative manufacturing stage of  FIG.  10 A , it should be appreciated that the majority of strong seals described above have been formed, mixing peel seal  60  and delivery peel seal  90  have been formed according to their specifications discussed above, administration port  16  has been fully formed including tear strip  28 , and administration port  16  has been inserted into and sealed to center section  54  of bottom strong seal  50 . Dual chamber bag  10  is open (not strong sealed) at the dashed line sections that eventually form powdered drug portion  48   b  of side seam  40   b  (lateral dashed line  128 ) and upper seam area  34   a  (upper dashed line  130 ). Lateral peel seal  120  is in tact and has been formed with opening or aperture  126 . 
     The formative manufacturing stage of  FIG.  10 A  may be said to be an initial filling stage in which diluent is introduced into diluent chamber  70  and an inert and/or getter gas is introduced into drug chamber  80 . In particular, diluent, e.g., dextrose or saline, may be pumped or gravity fed (in either case metered precisely) at a desired volume into diluent chamber  70  through the opening between sheets  12  and  14  formed at dashed line  130 . In one embodiment, immediately after the delivery of diluent into diluent chamber  70 , the opening between sheets  12  and  14  formed at dashed line  130  is sealed with a strong seal via any of the sealing methods discussed herein, such that upper seam  30  is fully formed (i) with upper seam at area  34   a  having oval  34  and (ii) to have a desired strong sealing strength. 
     Any of the gases or blends discussed above may be injected, e.g., under a slight pressure so as not unduly stress dual chamber container  10 , into drug chamber  80  at a desired volume through opening or aperture  126  formed in lateral peel seal  120 . Opening or aperture  126  may be sized to be large enough to allow air to be flushed out of drug chamber  80  around the outside of the inert gas delivery nozzle or tube by the injection of inert (and/or getter) gas. Or, if opening or aperture  126  more or less seals to the gas delivery nozzle or tube, a second small opening (not illustrated) may be provided to vent air pushed out of drug chamber  80  by the injected gas. 
     In one embodiment, immediately after the injection of the inert (and/or getter) gas, opening or aperture  126  (and second opening if provided) is sealed via any of the sealing methods discussed herein, such that lateral peel seal  120  is fully formed to have a desired sealing strength. The injected gas is thereby trapped within drug chamber  80  and is provided in a quantity such that sheets  12  and  14 , at least over a majority of drug chamber  80 , are separated. The injected gas servers dual purposes, namely, to (i) remove oxygen to help sterility and (ii) maintain sheets  12  and  14  to form a spaced relationship between the sheets, which helps to prevent the sheets from sticking to each other and also aids in the eventual opening of lateral peel seal  120 , as discussed in more detail below. 
     Each of the above-described steps performed in connection with  FIG.  10 A , and any steps leading up to  FIG.  10 A , may be performed in a non-aseptic environment. The steps in connection with  FIG.  10 B  however are performed in a sterilizing, e.g., steam sterilizing, environment. As discussed above, opening or aperture  126  no longer exists in lateral peel seal  120  of  FIG.  10 B . Upper seam  30  having upper seam at area  34   a  is fully formed and trimmed from the width illustrated in  FIG.  10 A  (or folded over for extra strength along upper seam) so as to have a desired width, and such that dashed line  130  forming the diluent filling opening no longer exists. 
     If steam sterilized, dual chamber container or bag  10  at  FIG.  10 B  is placed in an autoclave (along with many other such bags or containers) and subjected to steam for a designated amount of time. As mentioned above, steam is able to penetrate tear strip  28  to reach all surfaces of within administration port  16  between tear strip  28  and septum or insert  24 . It has also been found that while the remainder of the inside of administration port  16 , the inside of delivery administration area  98 , and the inside of drug chamber  80  are relatively dry, that steam sterilization nonetheless adequately sterilizes those inner volumes and the surfaces forming same. If needed, it is contemplated to increase the humidity of the inert and/or getter gas delivered to the diluent chamber  80  to, e.g., fifty to one-hundred percent humidity, to aid the steam sterilization of the drug chamber. Diluent chamber  70  having been filled with diluent is readily sterilized under steam sterilization. After steam sterilization, dual chamber bags  10  are allowed to dry, either in a stationary location and/or during transit. 
     After steam sterilization in  FIG.  10 B , container or bag  10  is dried and moved in an aseptic manner from the sterilizing station, e.g., steam sterilization autoclave, into a cleanroom which has a classification suitable for handling powdered drug  88 . In  FIG.  10 C , once inside the cleanroom, lateral peel seal  120  is opened. Because drug chamber  80  contains injected gas, sheets  12  and  14  are separated from each other, thereby providing support for opposing suction cups (or other structure) to assist in forming a suction attachment with drug chamber  80  and to ensure that a resulting pulling force is applied only to the sheet  12  or  14  to which the cup is in contact. 
     In one embodiment, with the injected gas maintaining sheets  12  and  14  in an open condition throughout at least a portion of drug chamber  80 , at least one suction cup (not illustrated) is suctioned to each of separated sheets  12  and  14 . In an embodiment, the at least one suction cup for sheet  12  is located approximately midway between peel seals  60  and  90  but closer to lateral peel seal  120  than to powdered drug portion  48   a  of side seam  40   a , e.g., one-third or one-quarter of the total width away from lateral peel seal  120  and two-thirds or three-quarters, respectively, of the total width away from powdered drug portion  48   a  of side seam  40   a . The at least one suction cup for sheet  14  is likewise located approximately midway between peel seals  60  and  90  but closer to lateral peel seal  120  than to powdered drug portion  48   a  of side seam  40   a , e.g., one-third or one-quarter of the total width away from lateral peel seal  120  and two-thirds or three-quarters, respectively, of the total width away from powdered drug portion  48   a  of side seam  40   a.    
     Once suctioned to sheets  12  and  14 , the suction cups are moved apart a specified distance to open lateral peel seal  120  a desired amount for powdered drug filling, and at a specified speed so as not to create undue force that may inadvertently open either one or both of peel seals  60  and  90 . The suctioning, e.g., pneumatic, used to suction the cups to sheets  12  and  14  may be terminated to release sheets  12  and  14  before, during or after the delivery of powdered drug  80 , as desired or needed. If before drug delivery, the insertion of a powdered drug insertion nozzle or tube (not illustrated) may be precise and forceful enough to fit through opened lateral peel seal  120  even if sheets  12  and  14  close together at dashed line  128  partially or fully. If during or after drug delivery, the insertion of a powdered drug nozzle or tube may rely on the suction cups to maintain lateral peel seal  120  in an open state so that the powdered drug nozzle or tube may readily enter drug chamber  80  to deliver the powdered drug. 
     Any of the powdered drugs listed herein may be injected and/or gravity fed in a metered and known quantity into drug chamber  80  after lateral peel seal  120  has been opened. As discussed earlier, such filling is performed in an aseptic, cleanroom environment. 
     In  FIG.  10 D , container or bag  10  filled will both diluent and powdered drug  88  is moved, for example, along a conveyor line within the cleanroom to a bag sealing mechanism that provides a final strong seal at powdered drug portion  48   b  of side seam  40   b , where lateral peel seal  120  resided previously. Dual chamber container or bag  10  is fully formed in  FIG.  10 D  except for two final steps, namely, (i) the peel seal application of removable cover or foil layers  100 , one layer  100  each to either side of drug chamber  80  and (ii) the overpouching of dual chamber container or bag  10  having the applied removable cover or foil layers  100 . 
     The formation of dual chamber container or bag  10  has been described in detail in connection with  FIGS.  10 A to  10 D .  FIG.  11    illustrates one method  150  listing the steps discussed above without the detail just provided, but wherein such detail is expressly incorporated. The order of the steps in  FIG.  11    may be changed as needed or desired (for example, blocks  154 ,  156  and  160  could be in a different order, while blocks  168  and  170  could be in a different order). 
     At oval  152 , method  150  begins. 
     At block  154 , the majority of strong seals are formed, leaving upper and lateral openings. 
     At block  156 , the mixing, delivery and lateral (with opening) peel seals are formed. 
     At block  158 , the bags are separated if formed together. 
     At block  160 , the administration port is fully formed. 
     At block  162 , the administration port is sealed to the bag sheets. 
     At block  164 , diluent is metered into the diluent chamber through the upper opening. 
     At block  166 , gas is injected into the drug chamber through the lateral opening. 
     At block  168 , the upper opening between the bag sheets is strong sealed closed. 
     At block  170 , the opening in the lateral peel seal is weak peel sealed closed. 
     At block  172 , the bag with diluent and injection gas is moved to sterilization station. 
     At block  174 , the bag including the administration port is sterilized and dried. 
     At block  176 , the sterilized bag is moved aseptically to a cleanroom. 
     At block  178 , the lateral peel seal is opened inside the cleanroom. 
     At block  180 , powdered drug is metered into the drug chamber through the opened lateral peel seal. 
     At block  182 , the lateral opening between the bag sheets is strong sealed. 
     At block  184 , opaque or foil seals are weak sealed to the bag sheets. 
     At block  186 , the dual chamber container or bag is overpouched. 
     At oval  188 , method  150  ends. 
     Alternative Method of Making 
     Referring now to  FIGS.  12 A to  12 E , dual chamber bag  10  is illustrated in various intermediate stages of manufacture using an alternative method than method  150 . Again, for purposes of illustration, opaque layers  100  are not shown. Also, only the element numbers relevant for  FIGS.  12 A to  12 E  are provided; however, each of the structure, functionality and alternatives discussed for any of the element numbers found in  FIGS.  1 A to  9    is applicable to dual chamber bag  10  prepared via the intermediate steps of  FIGS.  12 A to  12 E .  FIGS.  12 A to  12 E  are similar to  FIGS.  10 A to  10 D  in that corners  44  in  FIGS.  12 A to  12 E  are angled instead of curved. Another similarity is that an extra aperture  46  is formed in  FIGS.  10 A to  10 D and  12 A to  12 E . 
       FIG.  12 A  illustrates that in formative stages of dual chamber bag  10 , there are portions of certain peripheral edges of the bag where sheets  12  and  14  are not sealed together to have a strong seal. Those edges are indicated in dashed line. In particular,  FIG.  12 A  illustrates via dashed line  128  that sheets  12  and  14  are unsealed at powdered drug strong seal portion  48   a , which is illustrated as being sealed in  FIGS.  1 A to  3   , for example. Additionally,  FIG.  12 A  illustrates via dashed line  208  that sheets  12  and  14  are unsealed at the diluent portion of side seam  40   a , which is likewise illustrated as being sealed in  FIGS.  1 A to  3   , for example. Notably, dashed line  130  in  FIG.  10 A  is not provided in  FIG.  12 A  and is not needed to fill diluent chamber  70  with diluent in the method of making associated with  FIGS.  12 A to  12 E . Upper seam area  34   a  of upper seam  30  may be formed with the other strong seals of container or bag  10  as illustrated in  FIG.  12 A . 
     As with  FIGS.  10 A and  10 B ,  FIG.  12 A  illustrates that during the formative stages of dual chamber bag  10 , additional lateral peel seal  120  is provided. As before, lateral peel seal  120  includes a first end  122 , second end  124  and small opening or aperture  126 , which is sized to accept a discharge tube or nozzle of an injection gas filling station (not illustrated). Peel seal  120  again has a length sufficient to provide a suitable opening to receive powdered drug  88 . Lateral peel seal  120  may again be about 2 mm to about 10 mm wide and about 50 mm to about 90 mm long and have the same seal strength (force required to open), greater seal strength or a lower seal strength than delivery peel seal  90 . Lateral peel seal  120  may again have a seal strength of approximately seal of 1 to 5 N/15 mm, and in one embodiment be 3 N/15 mm. 
     The primary difference between the formative stage of container or bag in  FIGS.  12 A to  12 E  and that of  FIGS.  10 A to  10 C  is that in  FIG.  12 A  a second lateral and temporary peel seal  200  is provided to aseptically fill diluent chamber  70 . Lateral peel seal  200  is provided in place of the upper portion of strong side seal  40   a . It should be appreciated in viewing  FIGS.  10 A to  10 C and  12 A  that lateral and temporary peel seals  120  and  200  may be placed on either side  40   a  or  40   b  of the bag. Moreover, in  FIG.  12 A , lateral peel seals  120  and  200  may be placed on the same or opposing sides of the bag. 
     Diluent peel seal  200  may be formed to be the same as or slightly different than powdered drug peel seal  120 . Diluent peel seal  200  includes a first end  202  that extends to curved or angled corner  44  and a second end  204  that extends to upper seam  30 . Diluent peel seal  200  has a length sufficient to provide a suitable opening to receive diluent in a later manufacturing step. In a non-limiting example, diluent peel seal  200  may be about 2 mm to about 10 mm wide and about 50 mm to about 90 mm long and have the same seal strength (force required to open), greater seal strength or a lower seal strength than delivery peel seal  90 . In an embodiment, diluent peel seal  200  may have a seal strength of approximately seal of 1 to 5 N/15 mm, and in one embodiment be 3 N/15 mm. 
     Diluent peel seal  200  in the illustrated embodiment is initially formed with a small opening or aperture  206 , which is sized to accept a discharge tube or nozzle of an injection gas filling station (not illustrated). Opening or aperture  206  may for example be long enough to accept a 6 mm to 10 mm outer diameter injection gas filling tube or nozzle. The injection gas may again be inert, such as nitrogen, argon, carbon dioxide or mixtures thereof and/or include an oxygen “getter” gas, such as hydrogen or silane. 
     Primary differences between the method of making in  FIGS.  10 A to  10 D  and that of  FIGS.  12 A to  12 E  is that in  FIGS.  12 A to  12 E , (i) filling of both drug  88  and diluent is done aseptically in a cleanroom and (ii) two lateral and temporary peel seals  120  and  200  are employed.  FIG.  12 A  is formed in a non-ascetic environment. In the non-ascetic environment, the majority of strong seals (except at dashed lines  128  and  208 ) are formed, mixing peel seal  60  and delivery peel seal  90  are formed according to their specifications discussed above, administration port  16  is fully formed including tear strip  28 , and administration port  16  is inserted into and sealed to center section  54  of bottom strong seal  50 . Lateral drug peel seal  120  (with opening  126 ) and lateral diluent peel seal  200  (with opening  206 ) are also formed according to their specifications discussed above. 
     Next, injection gas is introduced into powdered drug chamber  80  and diluent chamber  70  via openings  126  and  206 , respectively. Openings  126  and  206  are then immediately closed to trap injection the gas within chambers  70  and  80 . 
     Next, each empty (except for injection gas) container or bag of  FIG.  12 A  is sterilized. Because the bag of  FIG.  12 A  is empty, steam sterilization is not optimal. Nevertheless, steam sterilization could be employed. Sterilization via ethylene oxide is also an option. More likely, however, the containers or bags of  FIG.  12 A  are irradiated, e.g., gamma or electron beam (Ebeam) radiation, sterilized. Once sterilized, the bags of  FIG.  12 A  are delivered in an aseptic manner to a cleanroom. In an embodiment, if multiple containers are formed together, they are separated at some point prior to entering the cleanroom. 
       FIGS.  12 B to  12 E  illustrate what happens to the container or bag of  FIG.  12 A  once inside the cleanroom. In  FIG.  12 B , once inside the cleanroom, lateral drug peel seal  120  is opened. Because drug chamber  80  contains injected gas, sheets  12  and  14  are separated from each other, thereby providing support for opposing suction cups (or other structure) to assist in forming a suction attachment with drug chamber  80  and to ensure that a resulting pulling force is applied only to the sheet  12  or  14  to which the cup is in contact. The use of suction cups or any other device for providing a pulling force, and all structure, functionality and alternatives for same discussed above in connection with  FIG.  10 C , is equally applicable to the opening of lateral drug peel seal  120  of  FIG.  12 B . 
     With peel seal  120  of  FIG.  12 B  opened, leaving the opening illustrated by dashed line  128 , any of the powdered drugs listed herein may be injected and/or gravity fed in a metered and known quantity into drug chamber  80 . Such filling is performed in the aseptic, cleanroom environment. Notably, in  FIG.  12 B , lateral diluent peel seal  200  for diluent chamber  70  remains in tact. 
     In  FIG.  12 C , with powdered drug  88  injected into powdered drug chamber  80 , powdered drug portion  48   a  of strong side seam  40   a  is formed aseptically, completing powdered drug chamber  80  and trapping powdered drug  88  within same. Notably, in  FIG.  12 C , lateral diluent peel seal  200  for diluent chamber  70  remains in tact. 
     In  FIG.  12 D , lateral diluent peel seal  200  is opened. Because diluent chamber  70  contains injected gas, sheets  12  and  14  are separated from each other, thereby providing support for opposing suction cups (or other structure) to assist in forming a suction attachment with diluent chamber  70  and to ensure that a resulting pulling force is applied only to the sheet  12  or  14  to which the cup is in contact. The use of suction cups or any other device for providing a pulling force, and all structure, functionality and alternatives for same discussed above in connection with  FIG.  10 C , is equally applicable to the opening of lateral diluent peel seal  200  of  FIG.  12 D . 
     With temporary peel seal  200  of  FIG.  12 D  opened, leaving the opening illustrated by dashed line  208 , any of the diluents listed herein may be injected and/or gravity fed in a metered and known quantity into diluent chamber  70 . Such filling is likewise performed in the aseptic, cleanroom environment. 
     In  FIG.  12 E , with diluent injected into diluent chamber  70 , diluent portion of strong side seam  40   a  between curved or angled corner  44  and upper seam  30  is formed aseptically, completing diluent chamber  70  and trapping the diluent within same. In  FIG.  12 E , dual chamber container or bag  10  is substantially formed except for the opaque layers  100  and the overpouch. 
     It should be appreciated that for both the methods of  FIGS.  10 A to  10 D and  12 A to  12 E , an in-process control step in which the desired quantity of powdered drug  88  is verified to have been metered to powdered drug chamber  80 . Such check may be made via one or both of a load cell sensor and/or a vision check. With the load cell, one or both of a weight of drug  88  added to container or bag  10  and/or a weight of drug  88  removed from a supply may be analyzed. Also, containers or bags  10  at  FIGS.  10 D and  12 E  may be washed and dried prior to the addition of opaque layers  100 , all of which may be performed non-aseptically along with the addition of the overpouch. Further, for both the methods of  FIGS.  10 A to  10 D and  12 A to  12 E , container or bag  10  may be leak checked prior to overpouching. 
     An alternative formation of dual chamber container or bag  10  has been described in detail in connection with  FIGS.  12 A to  12 E .  FIG.  13    illustrates one method  210  listing the steps discussed above without the detail just provided, but wherein such detail is expressly incorporated. The order of the steps in  FIG.  13    may be changed as needed or desired (for example, aseptic filling of diluent may occur before aseptic filling of powdered drug  80 , formation of seals may be switched, and administration port  16  may be formed at any time prior to its sealing). 
     At oval  212 , method  210  begins. 
     At block  214 , the majority of strong seals are formed, leaving drug and diluent lateral openings. 
     At block  216 , the mixing, delivery, and drug and diluent lateral (with openings) peel seals are formed. 
     At block  218 , the bags are separated if formed together. 
     At block  220 , the administration port is fully formed. 
     At block  222 , the administration port is sealed to the bag sheets. 
     At block  224 , gas is injected into the drug chamber through the lateral drug peel seal opening. 
     At block  226 , the lateral drug peel seal opening is weak peel sealed closed. 
     At block  228 , gas is injected into the diluent chamber through the lateral diluent peel seal opening. 
     At block  230 , the lateral diluent peel seal opening is weak peel sealed closed. 
     At block  232 , the bag with injection gas in both chambers is moved to a sterilization station. 
     At block  234 , the bag including the administration port is sterilized, e.g., gamma radiation sterilized. 
     At block  236 , the sterilized bag is moved aseptically to a cleanroom. 
     At block  238 , the lateral drug peel seal is opened inside the cleanroom. 
     At block  240 , powdered drug is metered into the drug chamber through the opened drug peel seal aseptically. 
     At block  242 , the opened drug peel seal is strong sealed closed. 
     At block  244 , the lateral diluent peel seal is opened inside the cleanroom. 
     At block  246 , diluent is metered into the diluent chamber through the opened diluent peel seal aseptically. 
     At block  248 , the opened diluent peel seal is strong sealed closed. 
     At block  250 , opaque or foil seals are weak sealed to the bag sheets. 
     At block  252 , the dual chamber container or bag is overpouched. 
     At oval  254 , method  210  ends. 
     Product Using Dual Chamber Bag 
     To reduce the volume and weight of powdered drug  88  needed, and to reduce the amount of aseptic filling that needs to be performed, it is contemplated to remove one or more component of dry drug powder  88  and to provide it instead with the liquid diluent. Components suitable for removal from the drug powder include buffers, tonicity adjusters or other soluble components normally provided with the powder. The removed component is provided instead in the liquid diluent, which may be particularly beneficial if there is a risk of interaction between the powdered components. 
     Similarly, it is possible that in the event that a very small volume of drug powder  88  is required, some fraction of the dextrose or sodium chloride ordinarily dissolved in the diluent might instead be provided in powder  88  to increase its volume for greater ease of handling. 
     It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims. For example, while the structure and functionality have been described in connection with a flexible bag, certain structure and functionality described herein are applicable to other types of fluid containers, such as other medical fluid containers. Also, while the structure and functionality have been described in connection with a dual chamber container, much of the structure and functionality described herein are applicable to containers having a single chamber or three or more chambers. Moreover, in an alternative embodiment, the gas insertion into the powdered drug chamber may be performed in the cleanroom after sterilization. In a further alternative embodiment, the powdered drug may be filled through the administration port instead of through the lateral peel seal, wherein the administration port is thereafter fitted with or formed to have septum or insert  24 .